Ocular manifestations of anti-neoplastic immune checkpoint inhibitor-associated Stevens-Johnson syndrome/toxic epidermal necrolysis in cancer patients
•SJS/TEN with severe ocular involvement can occur following immune checkpoint inhibitor treatment.•Causative ICIs included nivolumab, pembrolizumab, atezolizumab, durvalumab, and ipilimumab.•Poor survival of the patients due to advanced cancer stage.•Early and aggressive treatments are vital to prev...
Gespeichert in:
| Veröffentlicht in: | The ocular surface 2021-10, Vol.22, p.47-50 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 50 |
|---|---|
| container_issue | |
| container_start_page | 47 |
| container_title | The ocular surface |
| container_volume | 22 |
| creator | Ma, Kevin Sheng-Kai Saeed, Hajirah N. Chodosh, James Wang, Chuang-Wei Chung, Yu-Chien Wei, Li-Chen Kuo, Ming-Tse Liang, Chang-Min Chang, John Wen-Cheng Chung, Wen-Hung Chen, Chun-Bing Ma, David Hui-Kang |
| description | •SJS/TEN with severe ocular involvement can occur following immune checkpoint inhibitor treatment.•Causative ICIs included nivolumab, pembrolizumab, atezolizumab, durvalumab, and ipilimumab.•Poor survival of the patients due to advanced cancer stage.•Early and aggressive treatments are vital to prevent long-term ocular complication. |
| doi_str_mv | 10.1016/j.jtos.2021.06.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2548404505</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1542012421000604</els_id><sourcerecordid>2548404505</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-c57022c038b03ded101f0d8448d6f4506b740a7a0a7522ae0c1f5647d5ed13d23</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxiMEoqXwAhyQj1ySjh3b2ZW4oKr8U6UegLPltSdaL4kdPE7FvgjPi1dbOHKwxodvfjPffE3zmkPHgevrQ3coiToBgnegO-DwpLnk235o1Zb3T-tfSdECF_KieUF0AOi1BvG8ueil4HrYwmXz-96tk81stjGMSMWWkCKxNDIbS2gjpmWyVIJjYZ7XiMzt0f1YUoiFhbgPu1BSbi1RcsEW9OxrwQeM1H5J-0gpMjpGn9OM1yX9qhRcgsc824lFdDlNRwpUQczZ6DCzpc7HWOhl82y0E-Grx3rVfP9w--3mU3t3__Hzzfu71vVKl9apAYRw0G920Hv09Swj-I2UG69HqUDvBgl2sPUpISyC46PScvCqansv-qvm7Zm75PRzrf7NHMjhNNnqfCUjlNxIqCRVpeIsrWsTZRzNksNs89FwMKc8zMGc8jCnPAxoU_OoTW8e-etuRv-v5W8AVfDuLMDq8iFgNuTqBRz6kNEV41P4H_8PUGKghw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2548404505</pqid></control><display><type>article</type><title>Ocular manifestations of anti-neoplastic immune checkpoint inhibitor-associated Stevens-Johnson syndrome/toxic epidermal necrolysis in cancer patients</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Ma, Kevin Sheng-Kai ; Saeed, Hajirah N. ; Chodosh, James ; Wang, Chuang-Wei ; Chung, Yu-Chien ; Wei, Li-Chen ; Kuo, Ming-Tse ; Liang, Chang-Min ; Chang, John Wen-Cheng ; Chung, Wen-Hung ; Chen, Chun-Bing ; Ma, David Hui-Kang</creator><creatorcontrib>Ma, Kevin Sheng-Kai ; Saeed, Hajirah N. ; Chodosh, James ; Wang, Chuang-Wei ; Chung, Yu-Chien ; Wei, Li-Chen ; Kuo, Ming-Tse ; Liang, Chang-Min ; Chang, John Wen-Cheng ; Chung, Wen-Hung ; Chen, Chun-Bing ; Ma, David Hui-Kang</creatorcontrib><description>•SJS/TEN with severe ocular involvement can occur following immune checkpoint inhibitor treatment.•Causative ICIs included nivolumab, pembrolizumab, atezolizumab, durvalumab, and ipilimumab.•Poor survival of the patients due to advanced cancer stage.•Early and aggressive treatments are vital to prevent long-term ocular complication.</description><identifier>ISSN: 1542-0124</identifier><identifier>EISSN: 1937-5913</identifier><identifier>DOI: 10.1016/j.jtos.2021.06.010</identifier><identifier>PMID: 34216790</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Algorithm of drug causality for epidermal necrolysis ; Eye ; Humans ; Immune checkpoint inhibitor ; Immune Checkpoint Inhibitors ; Neoplasms ; Ocular surface grading score ; Stevens-Johnson syndrome ; Stevens-Johnson Syndrome - etiology ; Toxic epidermal necrolysis</subject><ispartof>The ocular surface, 2021-10, Vol.22, p.47-50</ispartof><rights>2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-c57022c038b03ded101f0d8448d6f4506b740a7a0a7522ae0c1f5647d5ed13d23</citedby><cites>FETCH-LOGICAL-c356t-c57022c038b03ded101f0d8448d6f4506b740a7a0a7522ae0c1f5647d5ed13d23</cites><orcidid>0000-0001-8373-5691 ; 0000-0003-3655-4059 ; 0000-0002-7921-4129 ; 0000-0003-1681-0959 ; 0000-0003-4159-0564 ; 0000-0003-1056-1533 ; 0000-0002-7378-4235 ; 0000-0002-7463-1599 ; 0000-0003-4745-8601</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34216790$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ma, Kevin Sheng-Kai</creatorcontrib><creatorcontrib>Saeed, Hajirah N.</creatorcontrib><creatorcontrib>Chodosh, James</creatorcontrib><creatorcontrib>Wang, Chuang-Wei</creatorcontrib><creatorcontrib>Chung, Yu-Chien</creatorcontrib><creatorcontrib>Wei, Li-Chen</creatorcontrib><creatorcontrib>Kuo, Ming-Tse</creatorcontrib><creatorcontrib>Liang, Chang-Min</creatorcontrib><creatorcontrib>Chang, John Wen-Cheng</creatorcontrib><creatorcontrib>Chung, Wen-Hung</creatorcontrib><creatorcontrib>Chen, Chun-Bing</creatorcontrib><creatorcontrib>Ma, David Hui-Kang</creatorcontrib><title>Ocular manifestations of anti-neoplastic immune checkpoint inhibitor-associated Stevens-Johnson syndrome/toxic epidermal necrolysis in cancer patients</title><title>The ocular surface</title><addtitle>Ocul Surf</addtitle><description>•SJS/TEN with severe ocular involvement can occur following immune checkpoint inhibitor treatment.•Causative ICIs included nivolumab, pembrolizumab, atezolizumab, durvalumab, and ipilimumab.•Poor survival of the patients due to advanced cancer stage.•Early and aggressive treatments are vital to prevent long-term ocular complication.</description><subject>Algorithm of drug causality for epidermal necrolysis</subject><subject>Eye</subject><subject>Humans</subject><subject>Immune checkpoint inhibitor</subject><subject>Immune Checkpoint Inhibitors</subject><subject>Neoplasms</subject><subject>Ocular surface grading score</subject><subject>Stevens-Johnson syndrome</subject><subject>Stevens-Johnson Syndrome - etiology</subject><subject>Toxic epidermal necrolysis</subject><issn>1542-0124</issn><issn>1937-5913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQxiMEoqXwAhyQj1ySjh3b2ZW4oKr8U6UegLPltSdaL4kdPE7FvgjPi1dbOHKwxodvfjPffE3zmkPHgevrQ3coiToBgnegO-DwpLnk235o1Zb3T-tfSdECF_KieUF0AOi1BvG8ueil4HrYwmXz-96tk81stjGMSMWWkCKxNDIbS2gjpmWyVIJjYZ7XiMzt0f1YUoiFhbgPu1BSbi1RcsEW9OxrwQeM1H5J-0gpMjpGn9OM1yX9qhRcgsc824lFdDlNRwpUQczZ6DCzpc7HWOhl82y0E-Grx3rVfP9w--3mU3t3__Hzzfu71vVKl9apAYRw0G920Hv09Swj-I2UG69HqUDvBgl2sPUpISyC46PScvCqansv-qvm7Zm75PRzrf7NHMjhNNnqfCUjlNxIqCRVpeIsrWsTZRzNksNs89FwMKc8zMGc8jCnPAxoU_OoTW8e-etuRv-v5W8AVfDuLMDq8iFgNuTqBRz6kNEV41P4H_8PUGKghw</recordid><startdate>202110</startdate><enddate>202110</enddate><creator>Ma, Kevin Sheng-Kai</creator><creator>Saeed, Hajirah N.</creator><creator>Chodosh, James</creator><creator>Wang, Chuang-Wei</creator><creator>Chung, Yu-Chien</creator><creator>Wei, Li-Chen</creator><creator>Kuo, Ming-Tse</creator><creator>Liang, Chang-Min</creator><creator>Chang, John Wen-Cheng</creator><creator>Chung, Wen-Hung</creator><creator>Chen, Chun-Bing</creator><creator>Ma, David Hui-Kang</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8373-5691</orcidid><orcidid>https://orcid.org/0000-0003-3655-4059</orcidid><orcidid>https://orcid.org/0000-0002-7921-4129</orcidid><orcidid>https://orcid.org/0000-0003-1681-0959</orcidid><orcidid>https://orcid.org/0000-0003-4159-0564</orcidid><orcidid>https://orcid.org/0000-0003-1056-1533</orcidid><orcidid>https://orcid.org/0000-0002-7378-4235</orcidid><orcidid>https://orcid.org/0000-0002-7463-1599</orcidid><orcidid>https://orcid.org/0000-0003-4745-8601</orcidid></search><sort><creationdate>202110</creationdate><title>Ocular manifestations of anti-neoplastic immune checkpoint inhibitor-associated Stevens-Johnson syndrome/toxic epidermal necrolysis in cancer patients</title><author>Ma, Kevin Sheng-Kai ; Saeed, Hajirah N. ; Chodosh, James ; Wang, Chuang-Wei ; Chung, Yu-Chien ; Wei, Li-Chen ; Kuo, Ming-Tse ; Liang, Chang-Min ; Chang, John Wen-Cheng ; Chung, Wen-Hung ; Chen, Chun-Bing ; Ma, David Hui-Kang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-c57022c038b03ded101f0d8448d6f4506b740a7a0a7522ae0c1f5647d5ed13d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Algorithm of drug causality for epidermal necrolysis</topic><topic>Eye</topic><topic>Humans</topic><topic>Immune checkpoint inhibitor</topic><topic>Immune Checkpoint Inhibitors</topic><topic>Neoplasms</topic><topic>Ocular surface grading score</topic><topic>Stevens-Johnson syndrome</topic><topic>Stevens-Johnson Syndrome - etiology</topic><topic>Toxic epidermal necrolysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ma, Kevin Sheng-Kai</creatorcontrib><creatorcontrib>Saeed, Hajirah N.</creatorcontrib><creatorcontrib>Chodosh, James</creatorcontrib><creatorcontrib>Wang, Chuang-Wei</creatorcontrib><creatorcontrib>Chung, Yu-Chien</creatorcontrib><creatorcontrib>Wei, Li-Chen</creatorcontrib><creatorcontrib>Kuo, Ming-Tse</creatorcontrib><creatorcontrib>Liang, Chang-Min</creatorcontrib><creatorcontrib>Chang, John Wen-Cheng</creatorcontrib><creatorcontrib>Chung, Wen-Hung</creatorcontrib><creatorcontrib>Chen, Chun-Bing</creatorcontrib><creatorcontrib>Ma, David Hui-Kang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The ocular surface</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, Kevin Sheng-Kai</au><au>Saeed, Hajirah N.</au><au>Chodosh, James</au><au>Wang, Chuang-Wei</au><au>Chung, Yu-Chien</au><au>Wei, Li-Chen</au><au>Kuo, Ming-Tse</au><au>Liang, Chang-Min</au><au>Chang, John Wen-Cheng</au><au>Chung, Wen-Hung</au><au>Chen, Chun-Bing</au><au>Ma, David Hui-Kang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ocular manifestations of anti-neoplastic immune checkpoint inhibitor-associated Stevens-Johnson syndrome/toxic epidermal necrolysis in cancer patients</atitle><jtitle>The ocular surface</jtitle><addtitle>Ocul Surf</addtitle><date>2021-10</date><risdate>2021</risdate><volume>22</volume><spage>47</spage><epage>50</epage><pages>47-50</pages><issn>1542-0124</issn><eissn>1937-5913</eissn><abstract>•SJS/TEN with severe ocular involvement can occur following immune checkpoint inhibitor treatment.•Causative ICIs included nivolumab, pembrolizumab, atezolizumab, durvalumab, and ipilimumab.•Poor survival of the patients due to advanced cancer stage.•Early and aggressive treatments are vital to prevent long-term ocular complication.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34216790</pmid><doi>10.1016/j.jtos.2021.06.010</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0001-8373-5691</orcidid><orcidid>https://orcid.org/0000-0003-3655-4059</orcidid><orcidid>https://orcid.org/0000-0002-7921-4129</orcidid><orcidid>https://orcid.org/0000-0003-1681-0959</orcidid><orcidid>https://orcid.org/0000-0003-4159-0564</orcidid><orcidid>https://orcid.org/0000-0003-1056-1533</orcidid><orcidid>https://orcid.org/0000-0002-7378-4235</orcidid><orcidid>https://orcid.org/0000-0002-7463-1599</orcidid><orcidid>https://orcid.org/0000-0003-4745-8601</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1542-0124 |
| ispartof | The ocular surface, 2021-10, Vol.22, p.47-50 |
| issn | 1542-0124 1937-5913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2548404505 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Algorithm of drug causality for epidermal necrolysis Eye Humans Immune checkpoint inhibitor Immune Checkpoint Inhibitors Neoplasms Ocular surface grading score Stevens-Johnson syndrome Stevens-Johnson Syndrome - etiology Toxic epidermal necrolysis |
| title | Ocular manifestations of anti-neoplastic immune checkpoint inhibitor-associated Stevens-Johnson syndrome/toxic epidermal necrolysis in cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T19%3A30%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ocular%20manifestations%20of%20anti-neoplastic%20immune%20checkpoint%20inhibitor-associated%20Stevens-Johnson%20syndrome/toxic%20epidermal%20necrolysis%20in%20cancer%20patients&rft.jtitle=The%20ocular%20surface&rft.au=Ma,%20Kevin%20Sheng-Kai&rft.date=2021-10&rft.volume=22&rft.spage=47&rft.epage=50&rft.pages=47-50&rft.issn=1542-0124&rft.eissn=1937-5913&rft_id=info:doi/10.1016/j.jtos.2021.06.010&rft_dat=%3Cproquest_cross%3E2548404505%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2548404505&rft_id=info:pmid/34216790&rft_els_id=S1542012421000604&rfr_iscdi=true |